ReviewHuman genetics2018
Personalised medicine and population health: breast and ovarian cancer.
Review in Human genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Early cardiotoxicity of radiotherapy in breast cancer patients after chemotherapy: the early warning sign.Journal of the Egyptian National Cancer Institute · 2026Observational
- Considering Clinical Implementation of Polygenic Scores in Hereditary Cancer Risk Assessment: Recipients' Perspectives on Influencing Factors and Strategies.The patient · 2025Article
- Haloperidol drug repurposing unveils ferroptosis involvement in breast cancer cells.Scientific reports · 2025Article
- Navigating heme pathways: the breach of heme oxygenase and hemin in breast cancer.Molecular and cellular biochemistry · 2025Review
- Toxicity, Half-Life and Antitumor Activity of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as Novel Antimitotic CYP1A1-Targeted Prodrugs in Female Mouse Models.Pharmaceutics · 2025Article
- Breast cancer imaging-clinical experience with two-dimensional-shear wave elastography: A retrospective study.World journal of radiology · 2024Article
- Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer.Cancers · 2023Review
- Multi-MicroRNA Analysis Can Improve the Diagnostic Performance of Mammography in Determining Breast Cancer Risk.The breast journal · 2023Article
- Review article: the future of microbiome-based therapeutics.Alimentary pharmacology & therapeutics · 2022Review
- Attitudes and interest in incorporating BRCA1/2 cancer susceptibility testing into reproductive carrier screening for Ashkenazi Jewish men and women.Journal of community genetics · 2022Article
- Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification.BMC medicine · 2022Article
- Sequencing of Chromosomal Locus 6q25.1 Revealed Two Significant SNPs rs2046210 and rs2046211 Associated with Breast Cancer: A Case-Control Study in Egyptian Women.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- BREAst screening Tailored for HEr (BREATHE)-A study protocol on personalised risk-based breast cancer screening programme.PloS one · 2022Article
- Complex Interventions Deserve Complex Evaluations: A Transdisciplinary Approach to Evaluation of a Preventive Personalized Medicine Intervention.Frontiers in public health · 2022Article
- Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.Breast cancer (Tokyo, Japan) · 2021Article
- Photodynamic Therapy Induced Cell Death Mechanisms in Breast Cancer.International journal of molecular sciences · 2021Review
- Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry.NPJ breast cancer · 2021Article
- Evaluation of Liposomal and Microbubbles Mediated Delivery of Doxorubicin in Two-Dimensional (2D) and Three-Dimensional (3D) Models for Breast Cancer.European journal of breast health · 2021Article
- Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.NPJ breast cancer · 2021Article
- Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of theOncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been suggested that a personalised approach to cancer prevention and screening might lead to a new paradigm for cancer control. Various aspects include testing for high-penetrance cancer susceptibility genes and generating personal risks scores, based on panels of single nucleotide polymorphisms. These tests can categorize women into various groupings of risk for cancer prevention (surgery and chemoprevention) cancer screening and prevention of cancer recurrence. In this review, I investigate various claims and come to the conclusion that the approach may be beneficial for the occasional patient but is unlikely to have any impact on reducing the burden of cancer incidence and mortality as whole. Challenges include meeting a high uptake of the test in the population, developing an effective and acceptable intervention and the willingness of healthy women to follow health care provider recommendations. The review focuses on strategies to reduce mortality from breast and ovarian cancer but is potentially applicable to other cancer sites, such as colon, prostate, and endometrial.
Indexed as
Identifiers
30328515What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.